MTNB

Business Context and Reporting Period

Company: Matinas BioPharma Holdings, Inc. (MTNB)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2026
Business Overview: A clinical-stage biopharmaceutical company focused on lipid nanocrystal (LNC) delivery technology. The Company is currently in a strategic transition phase, having entered into a Business Combination Agreement with GH Power Inc. and a Stock Purchase Agreement to sell its Nanotechnologies subsidiary (owner of MAT2203) to Azurity Pharmaceuticals, Inc. Following these transactions, the Company does not expect to continue its historical LNC Platform development activities as an independent public entity.

Key Financial Metrics

Liquidity Note: As of June 30, 2026, the Company had $761,000 in cash and cash equivalents. Management has expressed substantial doubt about the Company's ability to continue as a going concern without the consummation of the proposed strategic transactions or additional funding.

Material Changes vs. Prior Period

• Net Loss Reduction: Net loss decreased significantly from $6.9 million in the prior year period to $3.2 million. This improvement was primarily driven by the absence of a $3.2 million loss related to the change in fair value of warrant liability recorded in 2025.
• Operating Expenses: Total operating expenses decreased by approximately $293,000 (from $3.8M to $3.5M). This reduction is attributed to lower personnel costs due to headcount reductions and lower operating lease expenses following the termination of the Bridgewater facility lease in April 2026.
• Asset Disposal: The Company recognized a $138,000 loss on the disposal of assets in 2026 due to the write-off of leasehold improvements associated with the terminated Bridgewater lease. In contrast, a $110,000 gain was recorded in 2025 from the sale of equipment.
• Lease Termination Gain: A non-operating gain of $368,000 was recognized in 2026 resulting from the settlement and termination of the Bridgewater operating lease.
• Balance Sheet Contraction: Total assets decreased from $7.2 million (Dec 31, 2025) to $3.4 million (June 30, 2026), primarily due to the write-off of leasehold improvements and the reduction of operating lease right-of-use assets following the lease termination.

Outlook, Risks, and Subsequent Events

Strategic Transactions (Subsequent to June 30, 2026)

• Business Combination: Entered into an agreement with GH Power Inc. Current Matinas shareholders are expected to own approximately 9% of the combined entity (Pubco). The transaction is contingent on stockholder approval and a PIPE financing by GH Power.
• Asset Sale: Entered into a Stock Purchase Agreement to sell its Nanotechnologies subsidiary to Azurity Pharmaceuticals for up to $21.5 million ($4.0 million upfront, remainder in milestones) plus a mid-single-digit royalty on MAT2203 sales.
• Recent Financing:
  • Series D Financing: Closed July 10, 2026, raising net proceeds of approximately $575,000.
  • Warrant Inducement: Closed July 10, 2026, raising net proceeds of approximately $2.3 million through the exercise of 2025 warrants.

Risks and Contingencies

• Going Concern: Substantial doubt exists regarding the Company's ability to continue as a going concern if the Business Combination and Stock Sale are not consummated. The Board may pursue winddown or liquidation if additional funding is unavailable.
• Delisting Risk: The Company received notices from NYSE American regarding non-compliance with stockholders' equity requirements. While a plan to regain compliance was accepted, failure to meet the requirements by the deadline could result in delisting, which is a condition precedent to the Business Combination.
• Transaction Uncertainty: There is no assurance that the Business Combination or Stock Sale will close. Failure to close would require immediate capital raising, which may not be available on acceptable terms.

Investor Verification Checklist

• Transaction Closing Conditions: Verify the status of the required stockholder approvals for both the Business Combination with GH Power and the sale of Nanotechnologies to Azurity.
• Liquidity Runway: Confirm the total cash position post-subsequent financing ($761k + $575k + $2.3M) against the burn rate to assess the runway if transactions are delayed.
• NYSE American Compliance: Monitor the Company's progress in regaining compliance with stockholders' equity requirements to avoid delisting, which would block the merger.
• Ownership Dilution: Review the final exchange ratio for the Business Combination to confirm the approximate 9% ownership stake for current shareholders in the combined entity.
• Asset Sale Milestones: Understand the specific milestones required to trigger the remaining $17.5 million in potential consideration from Azurity.